There are currently no clearly defined parameters available for therapy management, as the updated S3 guideline on the diagnosis and treatment of Crohn’s disease published last year states. This is a dilemma that raises the question of other indicators for evaluating the course of treatment. In the PROFILE study, a treatment strategy involving the early use of a biologic proved to be superior to the standard procedure in terms of steroid-free and surgery-free remission.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Psoriasis in the Age of Precision Medicine
Systemic Therapy for Patients with Comorbidities: What Is the Best Choice?
- The AMALFI study and the limits of digital screening for atrial fibrillation
Remote monitoring for atrial fibrillation: lots of detection, little stroke prevention?
- MASH
Pharmacotherapies as “Game Changers”—What Are the Upcoming Challenges?
- Obesity Treatment
Oral GLP-1 Therapies: ATTAIN-1 and OASIS-4—The Next Leap Forward
- Older patients with atopic dermatitis
Why the Use of Biologics Is Recommended
- Disorders of the Gut-Brain Interaction
Peppermint-Caraway Oil Supplement Proves Effective in Phase IV Trial
- Gepante for Migraines
Relief from pain, symptoms, and improved functional ability—both acute and preventive
- Why the Finerenon Boom Is Giving Hyperkalemia Treatment New Relevance